Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
The Journal of Antimicrobial Chemotherapy
|
July 16, 2008
A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients
Joanne Sanders, Alan Pithie, Peter Ganly, et al.
British Journal of Haematology
|
June 13, 2002
A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia
Logan C Walker, Jane Stevens, Hamish Campbell, et al.
Leukemia & Lymphoma
|
August 26, 2011
Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome
Ian Nivison-Smith, Anthony J Dodds, Richard Doocey, et al.
Nature Genetics
|
January 17, 2017
Precision oncology for acute myeloid leukemia using a knowledge bank approach
Moritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, et al.
The Lancet. Haematology
|
March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Leukemia Research
|
May 1, 2010
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era
Dong-Wook Kim, Shripad D Banavali, Udomsak Bunworasate, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Paul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
European Journal of Haematology
|
March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma
Alessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
Blood
|
October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Hervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
The Journal of Antimicrobial Chemotherapy
|
July 16, 2008
A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients
Joanne Sanders, Alan Pithie, Peter Ganly, et al.
British Journal of Haematology
|
June 13, 2002
A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia
Logan C Walker, Jane Stevens, Hamish Campbell, et al.
Leukemia & Lymphoma
|
August 26, 2011
Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome
Ian Nivison-Smith, Anthony J Dodds, Richard Doocey, et al.
Nature Genetics
|
January 17, 2017
Precision oncology for acute myeloid leukemia using a knowledge bank approach
Moritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, et al.
The Lancet. Haematology
|
March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Leukemia Research
|
May 1, 2010
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era
Dong-Wook Kim, Shripad D Banavali, Udomsak Bunworasate, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Paul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
European Journal of Haematology
|
March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma
Alessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
Blood
|
October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Hervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
Page
of 3